New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
Eiger BioPharmaceuticals announced the publication of Phase 3 TOGETHER study results in the New England Journal of Medicine, indicating that peginterferon lambda significantly decreases clinical events in patients with mild-to-moderate COVID-19. The study reported a 51% reduction in hospitalization or emergency room visits (primary endpoint) and a 42% decrease in hospitalizations along with a 50% reduction in COVID-19-related deaths. Conducted among predominantly vaccinated participants, the results were consistent across various SARS-CoV-2 variants. The study involved 1,949 patients, with peginterferon lambda demonstrating benefits particularly when administered within three days of symptom onset.
- 51% reduction in hospitalization or emergency room visits in peginterferon lambda group vs. placebo.
- 42% reduction in risk of hospitalization and 50% in COVID-19 related deaths.
- Treatment effects consistent across multiple COVID-19 variants and vaccination status.
- High therapeutic potential of peginterferon lambda in COVID-19 and other viral infections.
- None.
- Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical events
- Lambda reduced risk of hospitalization or emergency room visits by
- Lambda reduced risk of hospitalization by
- Effects consistent across multiple dominant SARS-CoV-2 variants in a largely vaccinated population
"We are pleased to see the positive results from the TOGETHER study published in the
"Peginterferon lambda has tremendous therapeutic potential, and we continue to see the emergence of aggressive variants of the virus spreading around the globe which are less sensitive to both vaccines and treatment with antibodies," said
The primary endpoint was a composite endpoint of COVID-19-related hospitalization or emergency room visits greater than six hours. Secondary endpoints included SARS-CoV-2 viral clearance, all-cause hospitalization, mortality due to COVID-19, days in hospital and on ventilator, and adverse events. In the study, 931 patients received peginterferon lambda and 1018 received placebo. This was among the first trials to include a predominantly vaccinated population with
The publication detailed results, highlighting a
Peginterferon lambda was consistent in the direction of effect on all secondary outcomes. Risk of COVID-19 hospitalization or all-cause death was reduced by
"These data demonstrate the potential of peginterferon lambda to confer a meaningful benefit for patients with COVID-19 and suggests potential for other respiratory viral infections," said
About Peginterferon Lambda
Peginterferon lambda is an investigational late-stage, first-in-class, type III interferon (IFN) that stimulates immune responses that are critical for the development of host protection during viral infections and has been well-tolerated in clinical studies. Peginterferon lambda is to be administered as a single subcutaneous injection so that it can be prescribed and administered at the first sign of infection or at first awareness of an exposure, potentially helping patients avoid severe illness that can lead to hospitalization and death.
IFN lambdas are critical for maintaining a balanced antiviral response in the respiratory tract. They are induced at lower viral burden before type I IFNs to limit the initial infection by inducing viral resistance to cells and helping them deal with the virus load. IFN lambda lacks the strong pro-inflammatory effects of type I IFNs and are tissue-protective and anti-inflammatory.
About TOGETHER Study
TOGETHER is a multi-center, investigator-sponsored, randomized, placebo-controlled adaptive platform Phase 3 study evaluating therapeutics in newly diagnosed, high-risk, non-hospitalized patients with COVID-19. TOGETHER is the largest placebo-controlled study in COVID-19 and has evaluated 11 different therapeutic agents for non-hospitalized COVID-19 patients. This evaluation of peginterferon lambda versus placebo was the second largest study to date of a COVID-19 therapeutic. Eligibility criteria required that all patients had laboratory-confirmed mild-to-moderate COVID-19, and were randomized within seven days of symptom onset. High-risk criteria were defined by patients having at least one of the following, including but not limited to: > age 50, diabetes, hypertension, CV disease, lung disease, kidney disease, obesity, etc. The study enrolled patients regardless of vaccination status or variant strain of SARS-CoV-2. The primary endpoint was a clinical outcome comparing hospitalizations or emergency room visits greater than six hours after a single subcutaneous injection of peginterferon lambda versus placebo. The Data Safety Monitoring Board provided independent oversight for the trial and had previously discontinued other therapeutics due to observed futility. The TOGETHER study recruited from 12 sites in
For more information, please visit www.clinicaltrials.gov (NCT04727424, NCT04967430) and www.togethertrial.com.
About
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of our ongoing and planned clinical development; the sufficiency of our cash, cash equivalents and investments to fund our operations; the likelihood of identifying registration pathways for peginterferon lambda for COVID-19 and other respiratory viral infections; our capability to provide sufficient quantities of any of our product candidates to meet anticipated full-scale commercial demands; our ability to finance, independently or through collaborations, the continued advancement of our development pipeline and product launch; and the potential for success of any of our products or product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that
Contacts
Investors:
swheeler@wheelhouselsa.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-positive-phase-3-together-results-with-peginterferon-lambda-in-covid-19-301742477.html
SOURCE
FAQ
What did the Phase 3 TOGETHER study reveal about peginterferon lambda (EIGR) for COVID-19?
What are the implications of peginterferon lambda's results for EIGR's future?
How does peginterferon lambda perform against COVID-19 variants?
What were the study's key outcomes regarding mortality rates?